- Home
- FORA vs ASRT Comparison
FORA vs ASRT Comparison
Compare FORA & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FORA
- ASRT
- Stock Information
- Founded
- FORA 2014
- ASRT 1995
- Country
- FORA United States
- ASRT United States
- Employees
- FORA N/A
- ASRT N/A
- Industry
- FORA Computer Software: Prepackaged Software
- ASRT Biotechnology: Pharmaceutical Preparations
- Sector
- FORA Technology
- ASRT Health Care
- Exchange
- FORA Nasdaq
- ASRT Nasdaq
- Market Cap
- FORA 69.4M
- ASRT 79.1M
- IPO Year
- FORA N/A
- ASRT 1997
- Fundamental
- Price
- FORA $2.32
- ASRT $0.87
- Analyst Decision
- FORA Strong Buy
- ASRT Strong Buy
- Analyst Count
- FORA 1
- ASRT 1
- Target Price
- FORA $5.00
- ASRT $3.00
- AVG Volume (30 Days)
- FORA 20.7K
- ASRT 319.9K
- Earning Date
- FORA 11-12-2025
- ASRT 11-10-2025
- Dividend Yield
- FORA N/A
- ASRT N/A
- EPS Growth
- FORA N/A
- ASRT N/A
- EPS
- FORA N/A
- ASRT N/A
- Revenue
- FORA $25,031,040.00
- ASRT $117,099,000.00
- Revenue This Year
- FORA $47.82
- ASRT N/A
- Revenue Next Year
- FORA $10.11
- ASRT $4.10
- P/E Ratio
- FORA N/A
- ASRT N/A
- Revenue Growth
- FORA 18.59
- ASRT N/A
- 52 Week Low
- FORA $1.64
- ASRT $0.51
- 52 Week High
- FORA $4.03
- ASRT $1.16
- Technical
- Relative Strength Index (RSI)
- FORA 59.84
- ASRT 49.82
- Support Level
- FORA $2.20
- ASRT $0.87
- Resistance Level
- FORA $2.33
- ASRT $0.93
- Average True Range (ATR)
- FORA 0.07
- ASRT 0.04
- MACD
- FORA -0.01
- ASRT -0.01
- Stochastic Oscillator
- FORA 64.81
- ASRT 5.72
About FORA Forian Inc.
Forian Inc provides a suite of Software, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer, and provider segments, as well as cannabis dispensaries, manufacturers, and cultivators.
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.